AGARWALEYE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.5
| Stock Code | AGARWALEYE | Market Cap | 13,682 Cr. | Current Price | 434 ₹ | High / Low | 568 ₹ |
| Stock P/E | 232 | Book Value | 61.8 ₹ | Dividend Yield | 0.00 % | ROCE | 5.94 % |
| ROE | 1.31 % | Face Value | 1.00 ₹ | DMA 50 | 455 ₹ | DMA 200 | 459 ₹ |
| Chg in FII Hold | -0.07 % | Chg in DII Hold | -0.14 % | PAT Qtr | 14.6 Cr. | PAT Prev Qtr | 4.95 Cr. |
| RSI | 42.2 | MACD | -7.43 | Volume | 1,55,575 | Avg Vol 1Wk | 1,62,236 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | 1.52 | Debt to equity | 0.30 |
| 52w Index | 44.4 % | Qtr Profit Var | 80.3 % | EPS | 1.75 ₹ | Industry PE | 43.5 |
📊 Chart & Trend Analysis: AGARWALEYE is trading at ₹434, below both its 50 DMA (₹455) and 200 DMA (₹459), indicating bearish momentum. RSI at 42.2 suggests the stock is approaching oversold territory. MACD at -7.43 confirms negative momentum. Bollinger Bands show price leaning towards the lower band, with support near ₹327.
📈 Momentum Signals: Current volume (1.55 lakh) is slightly below the 1-week average (1.62 lakh), showing reduced participation. Weak RSI and negative MACD reinforce bearish bias, suggesting selling pressure dominates.
💡 Entry Zone: Optimal entry around ₹420–435 (near support).
🚪 Exit Zone: Resistance seen at ₹455 (50 DMA) and ₹459 (200 DMA). Profit booking advised near these levels.
🔎 Trend Status: The stock is currently consolidating with bearish bias. A breakout above ₹455–459 would indicate recovery momentum.
Positive
- Quarterly PAT growth (₹14.6 Cr vs ₹4.95 Cr) shows operational improvement.
- EPS of ₹1.75 provides earnings visibility.
- PEG ratio of 1.52 indicates reasonable growth relative to valuation.
- 52-week index gain of 44.4% highlights long-term strength.
Limitation
- Extremely high P/E (232) compared to industry average (43.5) suggests severe overvaluation.
- Weak ROCE (5.94%) and ROE (1.31%) indicate poor capital efficiency.
- Trading below both 50 DMA and 200 DMA highlights weak technical strength.
- Debt-to-equity ratio of 0.30 reflects moderate leverage risk.
Company Negative News
- Decline in FII holding (-0.07%) and DII holding (-0.14%) shows reduced institutional confidence.
- Low profitability metrics compared to peers.
Company Positive News
- Quarterly profit variation (+80.3% YoY) highlights strong growth momentum.
Industry
- Industry P/E at 43.5 is far lower than AGARWALEYE’s P/E, suggesting peers are more attractively valued.
- Healthcare and eye-care sector remains resilient, supported by rising demand for medical services and specialized treatments.
Conclusion
⚖️ AGARWALEYE shows operational improvement and sector resilience but faces valuation concerns and weak efficiency metrics. Short-term consolidation with bearish bias is evident. Entry near ₹420–435 offers margin of safety, while exits should be considered near ₹455–459. Long-term investors should be cautious given high valuations, while traders may wait for confirmation above 50 DMA before aggressive buying.
Would you like me to extend this into a peer benchmarking overlay (e.g., comparing AGARWALEYE with Dr. Agarwal’s competitors like Max Healthcare, Apollo Hospitals, and Narayana Hrudayalaya) to highlight relative strength and sector rotation opportunities?